Published in Cancer Weekly, March 20th, 2007
Position at the balance sheet date, summary:
2006 was a year of progress where the focus was on the integration and further development of the two new project portfolios from GemVax and Pharmexa-Epimmune. The most important result was the approval and initiation of a phase III study with the cancer vaccine GV1001 which has the potential to change the way cancer is treated in the future. Phase III studies are the final...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.